Primary Systemic Amyloidosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Primary Systemic Amyloidosis – Drugs In Development, 2024 report and make more profitable business decisions.
Primary systemic amyloidosis is a rare disorder in which abnormal proteins build up in tissues and organs. Clumps of the abnormal proteins are called amyloid deposits. It is plasma-cell dyscrasia characterized by an autonomous proliferation of plasma cells with an overproduction of a monoclonal Ig protein. The final pathway in the development of amyloidosis is the production of amyloid fibrils in the extracellular matrix.
The Primary Systemic Amyloidosis drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Systemic Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Systemic Amyloidosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Primary Systemic Amyloidosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Primary Systemic Amyloidosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Primary Systemic Amyloidosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Primary Systemic Amyloidosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Affiliated Hospital of Xuzhou Medical UniversityAlexion Pharmaceuticals Inc
Assertio Therapeutics Inc
Attralus Inc
Bristol-Myers Squibb Co
HaemaLogix Pty Ltd
Hangzhou Sumgen Biotech Co Ltd
Johnson & Johnson
Nanjing University
Nexcella Inc
Proclara Biosciences Inc
Prothena Corp Plc
Sanofi
Sorrento Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Primary Systemic Amyloidosis reports